NSD2 Inhibitor KTX-2001

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable small molecule inhibitor of the histone-lysine N-methyltransferase nuclear receptor-binding SET domain protein 2 (NSD2; multiple myeloma SET domain containing protein; MMSET; Wolf-Hirschhorn syndrome candidate 1 protein; WHSC1), with potential antineoplastic activity. Upon oral administration, NSD2 inhibitor KTX-2001 selectively targets and binds to NSD2, and inhibits its catalytic activity and the mono- and di-methylation of histone H3 lysine 36 (H3K36). This modulates the expression of genes involved in cellular processes including cellular proliferation, which may lead to decreased growth of cancer cells. NSD2, a member of the NSD family of histone lysine methyltransferase enzymes that catalyzes the mono- and di-methylation of H3K36, is overexpressed and dysregulated in many types of cancers.

**Synonyms:** - KTX 2001 - KTX-2001 - KTX2001 - MMSET Inhibitor KTX-2001 - Nuclear Receptor-binding SET Domain Protein 2 Inhibitor KTX-2001 - WHSC1 Inhibitor KTX-2001